This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Data availability
The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.
References
Childs R, Clave E, Contentin N, Jayasekera D, Hensel N, Leitman S, et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood. 1999;94:3234–41.
Khouri IF, Keating M, Korbling M, Przepiorka D, Anderlini P, O’Brien S, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol Off J Am Soc Clin Oncol. 1998;16:2817–24. https://doi.org/10.1200/JCO.1998.16.8.2817.
Khawaja MR, Perkins SM, Schwartz JE, Robertson MJ, Kiel PJ, Sayar H, et al. Cyclophosphamide/fludarabine nonmyeloablative allotransplant for acute myeloid leukemia. Am J Hematol. 2015;90:97–99. https://doi.org/10.1002/ajh.23875.
Nelson RP Jr, Yu M, Schwartz JE, Robertson MJ, Hromas R, Fausel CA, et al. Long-term disease-free survival after nonmyeloablative cyclophosphamide/fludarabine conditioning and related/unrelated allotransplantation for acute myeloid leukemia/myelodysplasia. Bone Marrow Transpl. 2010;45:1300–8. https://doi.org/10.1038/bmt.2009.348.
Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912–9. https://doi.org/10.1182/blood-2005-05-2004.
Davies JK, Taussig D, Oakervee H, Smith M, Agrawal S, Cavenagh JD, et al. Long-term survival with low toxicity after allogeneic transplantation for acute myeloid leukaemia and myelodysplasia using non-myeloablative conditioning without T cell depletion. Br J Haematol. 2013;162:525–9. https://doi.org/10.1111/bjh.12402.
Grigg AP, Gibson J, Bardy PG, Reynolds J, Shuttleworth P, Koelmeyer RL, et al. A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioning. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2007;13:560–7. https://doi.org/10.1016/j.bbmt.2006.12.449.
Muffly L, Pasquini MC, Martens M, Brazauskas R, Zhu X, Adekola K, et al. Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood. 2017;130:1156–64. https://doi.org/10.1182/blood-2017-03-772368.
Jethava YS, Sica S, Savani B, Socola F, Jagasia M, Mohty M, et al. Conditioning regimens for allogeneic hematopoietic stem cell transplants in acute myeloid leukemia. Bone Marrow Transpl. 2017;52:1504–11. https://doi.org/10.1038/bmt.2017.83.
Gyurkocza B, Storb R, Storer BE, Chauncey TR, Lange T, Shizuru JA, et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J Clin Oncol: Off J Am Soc Clin Oncol. 2010;28:2859–67. https://doi.org/10.1200/JCO.2009.27.1460.
Chevallier P, Berceanu A, Peterlin P, Garnier A, Le Bourgeois A, Imbert BM, et al. Grade 2 acute GVHD is a factor of good prognosis in patients receiving peripheral blood stem cells haplo-transplant with post-transplant cyclophosphamide. Acta Oncol. 2021;60:466–74. https://doi.org/10.1080/0284186X.2020.1837947.
Valcarcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB, et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26:577–84. https://doi.org/10.1200/JCO.2007.11.1641.
Acknowledgements
This work was supported by the Arlene Witmer Memorial Fund for Bone Marrow Cancer Research, the John and Denise Gilliland Fund for the Cancer Genetics Program, G. R. Sponaugle Employee Cancer Research Fund, Earl “Bumps” Clouser Memorial Lymphoma Research Endowment, and Richard E. and Stephanie A. Ziegler Charitable Foundation Endowment in Hematology. The authors would like to thank the patients who participated in this study and the technicians who participated in the experimental procedures.
Author information
Authors and Affiliations
Contributions
CP and KM drafted the paper under the supervision of HS, SM, and DC. CP, BS, and KM collected and analyzed patient data. SZ provided statistical input. JC, KR, MN, CE, WR, BW, SN, and HZ reviewed the paper and provided input.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethics approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Pizzola, C.J., Cioccio, J., Rakszawski, K.L. et al. Non-myeloablative allogeneic stem cell transplant with fludarabine and reduced dose cyclophosphamide in acute myeloid leukemia for older adults with comorbidities. Bone Marrow Transplant 57, 1743–1745 (2022). https://doi.org/10.1038/s41409-022-01821-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-022-01821-4